Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

IMPORTANCE: Older patients are underrepresented in studies of rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Little is known about outcomes and adverse events associated with the use of rituximab therapy among patients 75 years and older with ANCA-as...

Descripción completa

Detalles Bibliográficos
Autores principales: Thietart, Sara, Karras, Alexandre, Augusto, Jean-François, Philipponnet, Carole, Carron, Pierre-Louis, Delbrel, Xavier, Mesbah, Rafik, Blaison, Gilles, Duffau, Pierre, El Karoui, Khalil, Smets, Perrine, London, Jonathan, Mouthon, Luc, Guillevin, Loïc, Terrier, Benjamin, Puéchal, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270693/
https://www.ncbi.nlm.nih.gov/pubmed/35802372
http://dx.doi.org/10.1001/jamanetworkopen.2022.20925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270693/
https://www.ncbi.nlm.nih.gov/pubmed/35802372
http://dx.doi.org/10.1001/jamanetworkopen.2022.20925

Ejemplares similares